Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05463939 |
Expanded Access Status :
Approved for marketing
First Posted : July 19, 2022
Last Update Posted : November 15, 2022
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Relapsed or Refractory Multiple Myeloma | Drug: Teclistamab |
Study Type : | Expanded Access |
Expanded Access Type : | Treatment IND/Protocol |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma |
- Drug: Teclistamab
Teclistamab will be administered subcutaneously (SC).Other Name: JNJ-64007957
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Patient diagnosed with Relapsed or Refractory Multiple Myeloma
- Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05463939
Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT05463939 |
Other Study ID Numbers: |
CR109154 64007957MMY4001 ( Other Identifier: Janssen Research & Development, LLC ) |
First Posted: | July 19, 2022 Key Record Dates |
Last Update Posted: | November 15, 2022 |
Last Verified: | November 2022 |
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |